Management of chemical dependence in pregnancy

Clinical Obstetrics and Gynecology

Volumn 51, Issue 2, 2008, Pages 445-455

  Christensen, Carl ^a,b,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b DETROIT MEDICAL CENTER   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemical dependence; Illicit drugs; Pregnancy

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CLONIDINE; DISULFIRAM; FENTANYL; ILLICIT DRUG; LORAZEPAM; METHADONE; NALTREXONE; OPIATE;

ALCOHOL ABSTINENCE; ALCOHOL ABUSE; ALCOHOL WITHDRAWAL; ALCOHOLISM; BEHAVIOR THERAPY; BREAST FEEDING; CHILD WELFARE; COCAINE DEPENDENCE; COGNITIVE THERAPY; COMPULSION; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG INTERMITTENT THERAPY; DRUG INTOXICATION; DRUG MEGADOSE; DRUG SAFETY; DRUNKEN DRIVING; FETAL ALCOHOL SYNDROME; HEROIN DEPENDENCE; HUMAN; INTRAUTERINE GROWTH RETARDATION; LOW DRUG DOSE; MATERNAL WELFARE; METHADONE TREATMENT; MONOTHERAPY; MOTIVATION; MOTIVATIONAL ENHANCEMENT THERAPY; OPIATE ADDICTION; PATIENT ATTITUDE; PREGNANCY; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; REINFORCEMENT; REVIEW; REWARD; SCREENING TEST; SOLUTIO PLACENTAE; TWELVE STEP TREATMENT FACILITATION; WITHDRAWAL SYNDROME;

ALCOHOLISM; FEMALE; FETAL DISEASES; HUMANS; INFANT, NEWBORN; MASS SCREENING; NEONATAL ABSTINENCE SYNDROME; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RISK ASSESSMENT; RISK FACTORS; STREET DRUGS; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 43249118726     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/GRF.0b013e31816fea77     Document Type: Review

References (42)

1. Definitions related to the use of opioids for the treatment of pain: a consensus document from the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine. Available at: www.painmed.org/productpub/statements/pdfs/definition.pdf.
2. Cami J, Farre M. Mechanisms of disease: drug addiction.NEJM. 2003;349:975-986.
3. Volkow ND, Fowler JS, Wang GJ. Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behav Pharmacol. 2002;13:355-366.
4. Wang GJ, Volkow ND, Thanos PK, et al. Similarity between obesity and drug addiction as assessed by neurofunctional imaging: a concept review. J Addict Dis. 2004;23:39-53.
5. Volkow N, Wang GJ, Fowler JS, et al. Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study. Synapse. 2002;46:79-82.
6. Connors GJ, Tonigan JS, Miller WR. A longitudinal model of intake symptomatology, AA participation and outcome: retrospective study of the project MATCH outpatient and aftercare samples. J Stud Alcohol. 2001;62:817-825.
7. Christensen C. Physiology of Addiction. Dawn Farm Educational Series. Available at: http://www.dawnfarm.org/edseries_workshops.html.
8. Hartmann KE, Wechter ME, Payne P, et al. Best practice smoking cessation intervention and resource needs of prenatal care providers. Obet Gynecol. 2007;110:765-770.
9. The Patient Placement Criteria. In: Principles of Addiction Medicine. 3rd ed. 2004.
10. Chapter 2: Medical Guidelines for Pregnant, Substance-Using Women. In: SAMHSA/CSAT Treatment Improvement Protocol 2: Pregnant, Substance-Using Women. Available at: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat5.section. 22581#22691.
11. Winhusen T (PI). Motivational Enhancement Therapy to Improve Treatment Utilization in Pregnant Substance Users. Available at: http://clinicaltrials. gov/ct/show/NCT00078143?order=1.
12. Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Ped Adol Med. 2002;156:1129-1132.
13. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295:499-507.
14. Zuckerman B, Frank DA, Mayes L. Cocaine-exposed infants and developmental outcomes: "crack kids" revisited. JAMA. 2002;287:1990-1991.
15. McLellan AT, Lewis DC, O'Brien CP, et al. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284:1689-1695.
16. Harris LH, Paltrow L. The status of pregnant women and fetuses in US criminal law. JAMA. 2003;289:1697-1699.
17. ACOG Committee Opinion 294 May 2004: At-Risk Drinking and Illicit Drug Use: Ethical Issues in Obstetric and Gynecologic Practice.
18. Britton GR, Brinhaupt J, Stehle JM, et al. Comparison of self-reported smoking and urinary cotinine levels in a rural pregnant population. J Obstet Gynecol Neonatal Nurs. 2004;33:306-311.
19. Smith M, Garner D, Niemann JT. Pharmacologic interventions after an LD50 cocaine insult in a chronically instrument rat model: are beta-blockers contra-indicated? Ann Emerg Med. 1991;20:768-771.
20. Swotinsky R, Smith D. Laboratory Analysis. The Medical Review Officer's Manual. 3rd ed. Beverly Farms, MA: OEM Press.
21. Ferguson JA, Suelzer CJ, Eckert GJ, et al. Risk factors for delirium tremens development. J Gen Intern Med. 1996;11:410-414.
22. The Doctor's Opinion. Alcoholics Anonymous. 4th ed. Alcoholics Anonymous World Services Inc. xxviii.
23. Miller WR, Harris RJ. Simple scale of Gorski's warning signs for relapse. J Stud Alcohol. 2000;61:759-765.
24. Klein RF, Friedman-Campbell M, Tocco RV. History taking and substance abuse counseling with the pregnant patient. Clin Obstet Gynecol. 1993;36:338-346.
25. Dole V, Nyswander M. A medical treatment for diacetyl morphine addiction (heroin): a clinical trial with methadone hydrochloride. J Am Med Assoc. 1965;193:646-650.
26. White W. Slaying the Dragon: The History of Addiction Treatment and Recovery in America. Bloomington, IL: Chestnut Health Systems/Lighthouse Institute; 1998:251-256.
27. Chapter 5: Special Populations. In: SAMHSA Treatment Improvement Protocol 40: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Available at: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid= hstat5.section.72616.
28. DATA 2000. Available at: http://buprenorphine.samhsa.gov/fulllaw. html.
29. Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews. 2002, Issue 4. Art. No.: CD002207. DOI: 10.1002/14651858.CD002207.pub2.
30. Maas U, Kattner E, Weingart-Jesse B, et al. Infrequent neonatal, opiate withdrawal following maternal detoxification during pregnancy. J Perinat Med. 1990;18:111-118.
31. Luty J, Nikolaou V, Bearn J. Is opiate detoxification unsafe in pregnancy? J Sub Abuse Treat. 2003;24:363-367.
32. Dashe JS, Sheffield JS, Olscher DA, et al. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol. 2002;100:1244-1249.
33. Berghella V, Lim PJ, Hill MK, et al. Maternal methadone dose and neonatal withdrawal. Am J Obstet Gynecol. 2003;189:312-317.
34. Jansson LM, Velez M, Harrow C. Methadone maintenance and lactation: a review of the literature and current management guidelines. J Hum Lact. 2004;20:62-71.
35. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend. 2003;70(2 suppl):S87-S101.
36. Annitto WJ. Detoxification with buprenorphine of a pregnant heroin addict. Am J Addict. 2000;9:92-93.
37. Fischer G, Etzersdorfer P, Eder H, et al. Buprenorphine maintenance in pregnant opiate addicts. Eur Add Res. 1998;4(suppl 1):32-36.
38. Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double dummy comparison study. Addiction. 2006;101:275-281.
39. Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79:1-10.
40. Jones HE, Johnson RE, Milio L. Post-cesarean pain management of patients maintained on methadone or buprenorphine. Am J Addict. 2006;15:258-259.
41. Hoffman JR, Schriger DL, Luo JS. The empiric use of naloxone in patients with altered mental status: a reappraisal. Ann Emerg Med. 1991;20:246-252.
42. Weaver MF. ASAM. 3rd ed. p. 1239.